All In Biotech

Drug Trial Radar · NCT03961009

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients

Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

47

Actual

Start

Apr 30, 2019

Primary completion

Dec 21, 2020

Study completion Dec 21, 2020

Sponsor

Lead sponsor
Kedrion S.p.A.Industry
Sponsor type
Industry
First posted
May 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).

Conditions

  • Primary Immunodeficiency Disease

Interventions

  • Kedrion IVIG 10%Biological

    Kedrion intravenous immunoglobulin (IVIg) 10%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate of Acute Serious Bacterial Infections (ABSIs)Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Allergy Associates of the Palm Beaches

    North Palm Beach, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Dr. Henry J. Kanarek - Allergy, Asthma & Immunology

    Overland Park, Kansas

  • Midwest Immunology Clinic and Infusion Center

    Plymouth, Minnesota

  • Allergy and Immunology Associates

    Little Silver, New Jersey

  • University of Buffalo

    Buffalo, New York

  • Optimed Research

    Columbus, Ohio

  • Ohio Clinical Research Associates, Inc.

    Mayfield Heights, Ohio

  • Toledo Institute of Clinical Research Inc

    Toledo, Ohio

  • Allergy Partners of North Texas Research

    Dallas, Texas

  • AARA Research Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.